Biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics to treat immunological diseases.
Gossamer Bio, Inc., headquartered in San Diego, California, is a dynamic clinical-stage biopharmaceutical firm dedicated to advancing innovative therapies across immunology, inflammation, and oncology sectors within the United States. Established in 2015, the company specializes in the discovery, acquisition, development, and commercialization of cutting-edge treatments. Gossamer Bio's robust pipeline includes GB002, a pioneering inhaled small molecule targeting PDGFR, CSF1R, and c-KIT for pulmonary arterial hypertension, alongside GB004, an oral small molecule designed to treat inflammatory bowel disease, and GB5121, an oral Bruton's Tyrosine Kinase inhibitor for primary central nervous system lymphoma.
Underpinning its strategic growth trajectory, Gossamer Bio has cultivated pivotal partnerships to bolster its pipeline. Collaborations with Pulmokine, Inc. and Aerpio Pharmaceuticals, Inc. underscore the company's commitment to enhancing therapeutic options for patients. These alliances aim to leverage Gossamer Bio's scientific expertise and operational agility to advance novel treatments, addressing critical medical needs across diverse disease areas.
Formerly known as FSG Bio, Inc., Gossamer Bio rebranded in 2017, reflecting its evolution and expanded focus on groundbreaking biopharmaceutical advancements. With a steadfast dedication to scientific innovation and patient-centric research, Gossamer Bio continues to navigate the complexities of biotechnology, poised to deliver transformative therapies that have the potential to redefine standards of care worldwide.